Prelude Capital Management’s Wave Life Sciences WVE Stock Holding History

Prelude Capital Management’s Portfolio WVE Stock Details WVE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-93,202	Closed	-$1.58M	–	1635
2025 Q4	$1.58M	Buy	+93,202	New	+$947K	0.12%	192
2025 Q2	–	Sell	-109,330	Closed	-$883K	–	1408
2025 Q1	$883K	Buy	+109,330	New	+$1.2M	0.07%	341
2024 Q3	–	Sell	-135,200	Closed	-$675K	–	1580
2024 Q2	$675K	Sell	135,200 -9,100	-6%	-$51.9K	0.05%	418
2024 Q1	$890K	Buy	+144,300	New	+$723K	0.05%	427
2021 Q4	–	Sell	-13,893	Closed	-$68K	–	2289
2021 Q3	$68K	Buy	+13,893	New	+$84.2K	﹤0.01%	1534
2021 Q1	–	Sell	-27,294	Closed	-$215K	–	1854
2020 Q4	$215K	Buy	+27,294	New	+$229K	0.01%	1083

Other funds holding WVE

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

GSK plc London $602M AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Prelude Capital Management's WVE Position: Q1 2026 in Review

Prelude Capital Management sold out of Wave Life Sciences (WVE) in Q1 2026, closing a stake of 93,202 shares — an estimated $1.58M sold.

Prelude Capital Management first reported a position in WVE in Q4 2020 and held it in 6 quarters. The position peaked at $1.58M in Q4 2025. 232 funds tracked by Wall St. Rank hold WVE as of Q1 2026.

Prelude Capital Management reported no remaining Wave Life Sciences position as of Q1 2026 after selling out during the quarter.
Prelude Capital Management sold 93,202 Wave Life Sciences shares in Q1 2026, an estimated $1.58M.
Prelude Capital Management first reported a position in Wave Life Sciences in Q4 2020 and held it in 6 quarters.
Prelude Capital Management's Wave Life Sciences position peaked at $1.58M in Q4 2025.
232 funds tracked by Wall St. Rank held Wave Life Sciences as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.